Case Report: Use of Obinutuzumab as an Alternative Monoclonal Anti-CD20 Antibody in a Patient With Refractory Immune Thrombocytopenia Complicated by Rituximab-Induced Serum Sickness and Anti-Rituximab Antibodies

Management of refractory immune thrombocytopenia frequently involves rituximab, a chimeric anti-CD20 monoclonal antibody, to target B cells and induce remission in most patients. However, neutralizing antibodies to rituximab that nullify therapeutic response and may lead to serum sickness have been...

Descripción completa

Detalles Bibliográficos
Autores principales: Blase, Jennifer R., Frame, David, Michniacki, Thomas F., Walkovich, Kelly
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9061985/
https://www.ncbi.nlm.nih.gov/pubmed/35514985
http://dx.doi.org/10.3389/fimmu.2022.863177

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9061985/
https://www.ncbi.nlm.nih.gov/pubmed/35514985
http://dx.doi.org/10.3389/fimmu.2022.863177

Ejemplares similares